期刊
JOURNAL OF NEUROVIROLOGY
卷 22, 期 4, 页码 533-535出版社
SPRINGER
DOI: 10.1007/s13365-016-0427-6
关键词
Natalizumab; Progressive multifocal leukoencephalopathy (PML); Multiple sclerosis; Disease modifying therapy
资金
- Biogen
- Bristol Myers Squibb
- EMD Serono
- Forward Pharma
- Genzyme
- Genentech
- Inhibikase
- Incyte
- Janssen
- Johnson and Johnson
- Novartis
- Actelion
- Mallinckrodt
- MedDay
- Teva
- XenoPort
The risk algorithm for natalizumab-associated PML was first established in 2012 using the observations that JC virus antibody status, prolonged duration of natalizumab therapy (> 2 years), and prior exposure to immunosuppressive therapy increased the risk for the disease. Prior to the publication of Biogen's algorithm, a risk algorithm was created by Fox and Rudick using an Excel spreadsheet in order to address the concerns of their patients. Applying the most recently available data regarding natalizumab-associated PML, the risk assessments for PML were recalculated. The current numbers indicate substantially higher risks for PML in 2015 than in 2012. Our calculations suggest that an individual having all three risk factors has an approximately 1 in 44 chance of developing PML.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据